ShunzymeX addresses inherent challenges in traditional microbial downstream purification due to microbial-expressed protein diversity.

From analytical control through downstream processes to manufacturing, BsAbs present challenges in protein expression, purity, and stability.

Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

FUJIFILM Biotechnologies introduces ShunzymeX precision purification technology for downstream processing of complex biologics: Teessid, United Kingdom Thursday, March 5, 2026, 16 ...

TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to ...

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost Approximately ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GreenFuel Technologies Corporation, a leading developer of algae bioreactor systems that recycle carbon dioxide emissions into clean renewable biofuels and other ...

Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics ...

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before ...

TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization ...